Nuvalent

Yahoo Finance • 6 days ago

Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC

New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical compa... Full story

Yahoo Finance • 22 days ago

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

On February 17, 2026, Paradigm Biocapital Advisors LP disclosed a buy of 750,000 shares of Olema Pharmaceuticals(NASDAQ:OLMA) in Q4 2025, an estimated $13.35 million trade based on quarter-end pricing. What happened According to a Securi... Full story

Yahoo Finance • last month

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story

Yahoo Finance • last month

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline

On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines(NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average pricing. What happened According to a f... Full story

Yahoo Finance • 2 months ago

Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans

Nuvalent logo Nuvalent (NASDAQ:NUVL) executives highlighted ongoing regulatory milestones for the company’s lead oncology programs and discussed commercialization strategy, pipeline plans, and financial positioning during a conference fir... Full story

Yahoo Finance • 3 months ago

3 Biotech Stocks With Major 2026 Catalysts

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among investors rebounded sharply, powering a no... Full story

Yahoo Finance • 4 months ago

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that... Full story

Yahoo Finance • 4 months ago

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors

Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable ass... Full story

Yahoo Finance • 5 months ago

FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer

[Medical Illustration showing lung cancer or bronchial carcinoma. 3d illustration] * The US FDA has accepted an NDA from Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for zidesamtinib to treat non-small cell lung cancer. * Th... Full story

Yahoo Finance • 5 months ago

Biotech Stock Gets Booted in Latest Fund Update

Key Points Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift These 10 st... Full story

Yahoo Finance • 5 months ago

Nuvalent Announces Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that... Full story

Yahoo Finance • 8 months ago

Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year

Nuvalent, Inc. (NASDAQ:NUVL), a biopharmaceutical company focused on developing precision cancer therapies, stands at a critical juncture in its journey to bring novel treatments to market. With a robust pipeline and upcoming catalysts, Nu... Full story

Yahoo Finance • 8 months ago

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

CAMBRIDGE, Mass., Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that... Full story

Yahoo Finance • 8 months ago

Nuvalent Inc-A (NASDAQ:NUVL) Reports Q2 2025 Earnings Miss with Focus on Oncology Pipeline Progress

Nuvalent Inc-A (NASDAQ:NUVL [https://www.chartmill.com/stock/quote/NUVL]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$1.31, slightly missing analyst estimates of -$1.26. Revenue for the quarter ca... Full story

Yahoo Finance • 8 months ago

Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug

CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.5 billion, has initiated a rolling New Drug Application (NDA) submission for zidesamtinib, its ROS1-selective in... Full story

Yahoo Finance • 9 months ago

Goldman Sachs initiates coverage on Nuvalent stock with Buy rating

Investing.com - Goldman Sachs initiated coverage on Nuvalent (NASDAQ:NUVL) with a Buy rating and a price target of $105.00, according to a research note released Monday. The company, currently valued at $5.5 billion, maintains strong fin... Full story

Yahoo Finance • 10 months ago

Nuvalent chief development officer Noci sells $314k in shares

NUVL Chief Development Officer Darlene Noci sold a total of 4,000 shares of Nuvalent, Inc. (NASDAQ: NUVL) Class A Common Stock on June 26, 2025, for approximately $314,825. The shares were sold in multiple transactions at prices ranging fr... Full story

Yahoo Finance • 10 months ago

Nuvalent price target raised to $140 from $125 at Leerink

Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent’s zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by “unprec... Full story

Yahoo Finance • 10 months ago

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nuvalent (NUVL) to $130 from $110 and keeps a Buy rating on the shares. The company reported positive topline results from the Phase 1/2 ARROS-1 study evaluat... Full story

Yahoo Finance • 10 months ago

Nuvalent plans FDA submission for lung cancer drug zidesamtinib

CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ:NUVL), a $5.4 billion market cap biotechnology company with strong financial health according to InvestingPro metrics, plans to initiate a rolling New Drug Application (NDA) submission in July 2025... Full story